- Home
- CRGX vs KROS Comparison
CRGX vs KROS Comparison
Compare CRGX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- KROS
- Stock Information
- Founded
- CRGX 2021
- KROS 2015
- Country
- CRGX United States
- KROS United States
- Employees
- CRGX N/A
- KROS N/A
- Industry
- CRGX
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- KROS Health Care
- Exchange
- CRGX Nasdaq
- KROS Nasdaq
- Market Cap
- CRGX 190.0M
- KROS 558.9M
- IPO Year
- CRGX 2023
- KROS 2020
- Fundamental
- Price
- CRGX $4.40
- KROS $13.41
- Analyst Decision
- CRGX Hold
- KROS Buy
- Analyst Count
- CRGX 7
- KROS 13
- Target Price
- CRGX $4.67
- KROS $20.63
- AVG Volume (30 Days)
- CRGX 527.8K
- KROS 606.6K
- Earning Date
- CRGX 08-11-2025
- KROS 08-06-2025
- Dividend Yield
- CRGX N/A
- KROS N/A
- EPS Growth
- CRGX N/A
- KROS N/A
- EPS
- CRGX N/A
- KROS 0.11
- Revenue
- CRGX N/A
- KROS $214,713,000.00
- Revenue This Year
- CRGX $57.81
- KROS $5,006.76
- Revenue Next Year
- CRGX N/A
- KROS N/A
- P/E Ratio
- CRGX N/A
- KROS $122.43
- Revenue Growth
- CRGX N/A
- KROS 91657.70
- 52 Week Low
- CRGX $3.00
- KROS $9.12
- 52 Week High
- CRGX $25.45
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CRGX 55.41
- KROS 42.34
- Support Level
- CRGX $4.09
- KROS $13.25
- Resistance Level
- CRGX $4.31
- KROS $13.99
- Average True Range (ATR)
- CRGX 0.19
- KROS 0.39
- MACD
- CRGX -0.01
- KROS -0.06
- Stochastic Oscillator
- CRGX 61.61
- KROS 22.49
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.